Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 1, 2023

Details for Patent: 9,931,305

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,931,305 protect, and when does it expire?

Patent 9,931,305 protects SUBOXONE and KYNMOBI and is included in two NDAs.

This patent has one hundred and sixty-one patent family members in eighteen countries.

Summary for Patent: 9,931,305

Title:	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Abstract:	The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.
Inventor(s):	Yang; Robert K. (Henderson, NV), Fuisz; Richard C. (Beverly Hills, CA), Myers; Garry L. (Kingsport, TN), Fuisz; Joseph M. (Surfside, FL)
Assignee:	MonoSol Rx, LLC (Warren, NJ)
Application Number:	15/438,458
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,931,305
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 9,931,305

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-001	Aug 30, 2010	AB	RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012	AB	RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	AB	RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
Indivior Inc	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012	AB	RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
Sunovion Pharms Inc	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-001	May 21, 2020		RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
Sunovion Pharms Inc	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-002	May 21, 2020		RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,931,305

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077803	See Plans and Pricing
Austria	536868	See Plans and Pricing
Austria	536869	See Plans and Pricing
Austria	553746	See Plans and Pricing
Australia	2002332118	See Plans and Pricing
Australia	2002348432	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Johnson and Johnson

McKesson

Moodys

Baxter

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.